{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:55:43Z","timestamp":1768881343218,"version":"3.49.0"},"reference-count":69,"publisher":"Bentham Science Publishers Ltd.","issue":"13","funder":[{"DOI":"10.13039\/501100004517","name":"School of Pharmaceutical Science and Technology (SPST), Tianjin University","doi-asserted-by":"publisher","award":["290- 0903071002"],"award-info":[{"award-number":["290- 0903071002"]}],"id":[{"id":"10.13039\/501100004517","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2019,7,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Aurora A (AurA) kinase is a key mitotic protein implicated in cancer. Several\nsmall molecule inhibitors targeting the ATP binding site of this enzyme are in various stages of clinical\ndevelopment. However, these inhibitors can result in selectivity and drug resistance problems. Allosteric\ninhibition of kinases using small molecules is an alternative strategy to target these enzymes selectively\nand these could serve as the seeds for next generation medicines. This review discusses the\ndevelopments in the non-ATP site binding small molecule inhibitors of AurA and their prospect as\nfuture therapeutics.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p> Allosteric targeting of AurA kinase using small molecules is relatively a new strategy, and\nonly a handful of research work has been reported. Two patents and three papers pertaining to allosteric\ntargeting of AurA kinase using small molecules were covered in this review. Topics discussed\ninclude, identification of small molecule inhibitors targeting AurA- Targeting Protein for Xenopus\nkinesin-like protein 2 (TPX2) interaction, anacardic acid - a natural product ligand that selectively\nmodulates AurA activity in the presence of Aurora B kinase, and identification of felodipine as an uncompetitive\ninhibitor of AurA using Surface Enhanced Raman Spectroscopy (SERS) technique<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Allosteric targeting of therapeutically relevant enzymes using small molecules is a burgeoning\nresearch area. New techniques such as fragment-based ligand discovery, SERS methods, etc.,\nare expanding to identify the allosteric site binding ligands. Research in this area is expected to deliver\nfruitful outcome in terms of novel therapeutics against AurA kinase as well as other therapeutically\nrelevant enzymes.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867324666170727120315","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T07:57:45Z","timestamp":1501142265000},"page":"2234-2242","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?"],"prefix":"10.2174","volume":"26","author":[{"given":"Resmi C.","family":"Panicker","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin-3000072, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G.","family":"Coyne","sequence":"additional","affiliation":[{"name":"University Chemical Laboratory, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajavel","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin-3000072, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"872","volume":"7","author":"Shokat K.","year":"2002","unstructured":"Shokat K, Velleca M.  Novel chemical genetic approaches to the discovery of signal transduction inhibitors. [http:\/\/dx.doi.org\/10.1016\/S1359-6446(02)02391-7]. [PMID: 12546954].","journal-title":"Drug Discov Today"},{"key":"ref=2","first-page":"2209","volume":"101","author":"Johnson L.N.","year":"2001","unstructured":"Johnson LN, Lewis RJ.  Structural basis for control by phosphorylation. [http:\/\/dx.doi.org\/10.1021\/cr000225s]. [PMID: 11749371].","journal-title":"Chem Rev"},{"key":"ref=3","first-page":"547","volume":"8","author":"Lapenna S.","year":"2009","unstructured":"Lapenna S, Giordano A.  Cell cycle kinases as therapeutic targets for cancer. [http:\/\/dx.doi.org\/10.1038\/nrd2907]. [PMID: 19568282].","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","first-page":"927","volume":"4","author":"Keen N.","year":"2004","unstructured":"Keen N, Taylor S.  Aurora-kinase inhibitors as anticancer agents. [http:\/\/dx.doi.org\/10.1038\/nrc1502]. [PMID: 15573114].","journal-title":"Nat Rev Cancer"},{"key":"ref=5","first-page":"278","volume":"5","author":"Bavetsias V.","year":"2015","unstructured":"Bavetsias V, Linardopoulos S.  Aurora kinase inhibitors: Current status and outlook. [http:\/\/dx.doi.org\/10.3389\/fonc.2015.00278]. [PMID: 26734566].","journal-title":"Front Oncol"},{"key":"ref=6","first-page":"339","volume":"33","author":"Coghlan M.P.","year":"2005","unstructured":"Coghlan MP, Smith DM.  Introduction to the kinases in diabetes biochemical society focused meeting: Are protein kinases good targets for antidiabetic drugs? [http:\/\/dx.doi.org\/10.1042\/BST0330339]. [PMID: 15787601].","journal-title":"Biochem Soc Trans"},{"key":"ref=7","first-page":"27","volume":"426","author":"Nandipati K.C.","year":"2017","unstructured":"Nandipati KC, Subramanian S, Agrawal DK.  Protein kinases: Mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. [http:\/\/dx.doi.org\/10.1007\/s11010-016-2878-8]. [PMID: 27868170].","journal-title":"Mol Cell Biochem"},{"key":"ref=8","first-page":"219","volume":"387","author":"Williams N.K.","year":"2009","unstructured":"Williams NK, Bamert RS, Patel O, Wang C, Walden PM, Wilks AF, Fantino E, Rossjohn J, Lucet IS.  Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. [http:\/\/dx.doi.org\/10.1016\/j.jmb.2009.01.041]. [PMID: 19361440].","journal-title":"J Mol Biol"},{"key":"ref=9","first-page":"1355","volume":"25","author":"Semerano L.","year":"2016","unstructured":"Semerano L, Decker P, Clavel G, Boissier MC.  Developments with investigational Janus kinase inhibitors for rheumatoid arthritis. [http:\/\/dx.doi.org\/10.1080\/13543784.2016.1249565]. [PMID: 27748152].","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=10","first-page":"992","volume":"12","author":"Kutluk Cenik B.","year":"2013","unstructured":"Kutluk Cenik B, Ostapoff KT, Gerber DE, Brekken RA.  BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. [http:\/\/dx.doi.org\/10.1158\/1535-7163.MCT-12-0995]. [PMID: 23729403].","journal-title":"Mol Cancer Ther"},{"key":"ref=11","first-page":"892","volume":"8","author":"Chico L.K.","year":"2009","unstructured":"Chico LK, Van Eldik LJ, Watterson DM.  Targeting protein kinases in central nervous system disorders. [http:\/\/dx.doi.org\/10.1038\/nrd2999]. [PMID: 19876042].","journal-title":"Nat Rev Drug Discov"},{"key":"ref=12","first-page":"2532","volume":"12","author":"Zhuo Z.H.","year":"2016","unstructured":"Zhuo ZH, Sun YZ, Jin PN, Li FY, Zhang YL, Wang HL.  Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy. [http:\/\/dx.doi.org\/10.1039\/C6MB00297H]. [PMID: 27263470].","journal-title":"Mol Biosyst"},{"key":"ref=13","first-page":"1217","volume":"19","author":"Altman A.","year":"2014","unstructured":"Altman A, Kong KF.  Protein kinase C inhibitors for immune disorders. [http:\/\/dx.doi.org\/10.1016\/j.drudis.2014.05.008]. [PMID: 24892801].","journal-title":"Drug Discov Today"},{"key":"ref=14","first-page":"604","volume":"35","author":"Rask-Andersen M.","year":"2014","unstructured":"Rask-Andersen M, Zhang J, Fabbro D, Schi\u00f6th HB.  Advances in kinase targeting: Current clinical use and clinical trials. [http:\/\/dx.doi.org\/10.1016\/j.tips.2014.09.007]. [PMID: 25312588].","journal-title":"Trends Pharmacol Sci"},{"key":"ref=15","unstructured":"http:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrug\/ [Accessed: December 03, 2016]."},{"key":"ref=16","first-page":"59","volume":"156","author":"Wu P.","year":"2015","unstructured":"Wu P, Clausen MH, Nielsen TE.  Allosteric small-molecule kinase inhibitors. [http:\/\/dx.doi.org\/10.1016\/j.pharmthera.2015.10.002]. [PMID: 26478442].","journal-title":"Pharmacol Ther"},{"key":"ref=17","first-page":"422","volume":"36","author":"Wu P.","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH.  FDA-approved small-molecule kinase inhibitors. [http:\/\/dx.doi.org\/10.1016\/j.tips.2015.04.005]. [PMID: 25975227].","journal-title":"Trends Pharmacol Sci"},{"key":"ref=18","first-page":"5","volume":"21","author":"Wu P.","year":"2016","unstructured":"Wu P, Nielsen TE, Clausen MH.  Small-molecule kinase inhibitors: An analysis of FDA-approved drugs. [http:\/\/dx.doi.org\/10.1016\/j.drudis.2015.07.008]. [PMID: 26210956].","journal-title":"Drug Discov Today"},{"key":"ref=19","first-page":"293","volume":"118","author":"Gibbons D.L.","year":"2012","unstructured":"Gibbons DL, Pricl S, Kantarjian H, Cortes J, Quint\u00e1s-Cardama A.  The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. [http:\/\/dx.doi.org\/10.1002\/cncr.26225]. [PMID: 21732333].","journal-title":"Cancer"},{"key":"ref=20","first-page":"345","volume":"7","author":"Weisberg E.","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.  Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. [http:\/\/dx.doi.org\/10.1038\/nrc2126]. [PMID: 17457302].","journal-title":"Nat Rev Cancer"},{"key":"ref=21","unstructured":"28,463(7280),501-506."},{"key":"ref=22","first-page":"29","volume":"3","author":"Cox K.J.","year":"2011","unstructured":"Cox KJ, Shomin CD, Ghosh I.  Tinkering outside the kinase ATP box: Allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. [http:\/\/dx.doi.org\/10.4155\/fmc.10.272]. [PMID: 21428824].","journal-title":"Future Med Chem"},{"key":"ref=23","first-page":"1001","volume":"450","author":"Wells J.A.","year":"2007","unstructured":"Wells JA, McClendon CL.  Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. [http:\/\/dx.doi.org\/10.1038\/nature06526]. [PMID: 18075579].","journal-title":"Nature"},{"key":"ref=24","first-page":"2170","volume":"37","author":"Liu F.","year":"2016","unstructured":"Liu F, Wang J, Yang L, Liu L, Ding S, Fu M, Deng L, Gao LQ.  Developing a fluorescence-coupled capillary electrophoresis based method to probe interactions between QDs and colorectal cancer targeting peptides. [http:\/\/dx.doi.org\/10.1002\/elps.201600165]. [PMID: 27159348].","journal-title":"Electrophoresis"},{"key":"ref=25","first-page":"2156","volume":"37","author":"Wang J.","year":"2016","unstructured":"Wang J, Zhang C, Liu L, Kalesh KA, Qiu L, Ding S, Fu M, Gao LQ, Jiang P.  A capillary electrophoresis method to explore the self-assembly of a novel polypeptide ligand with quantum dots. [http:\/\/dx.doi.org\/10.1002\/elps.201600164]. [PMID: 27334251].","journal-title":"Electrophoresis"},{"key":"ref=26","first-page":"78","volume":"35","author":"Fischer G.","year":"2015","unstructured":"Fischer G, Rossmann M, Hyv\u00f6nen M.  Alternative modulation of protein-protein interactions by small molecules. [http:\/\/dx.doi.org\/10.1016\/j.copbio.2015.04.006]. [PMID: 25935873].","journal-title":"Curr Opin Biotechnol"},{"key":"ref=27","first-page":"2655","volume":"2","author":"Srinivasan R.","year":"2007","unstructured":"Srinivasan R, Li J, Ng SL, Kalesh KA, Yao SQ.  Methods of using click chemistry in the discovery of enzyme inhibitors. [http:\/\/dx.doi.org\/10.1038\/nprot.2007.323]. [PMID: 18007601].","journal-title":"Nat Protoc"},{"key":"ref=28","first-page":"713","volume":"8","author":"Srinivasan R.","year":"2006","unstructured":"Srinivasan R, Uttamchandani M, Yao SQ.  Rapid assembly and  screening of bidentate inhibitors of protein tyrosine phosphatases. [http:\/\/dx.doi.org\/10.1021\/ol052895w]. [PMID: 16468749].","journal-title":"Org Lett"},{"key":"ref=29","first-page":"385","volume":"11","author":"Zhao Y.","year":"2014","unstructured":"Zhao Y, Adjei AA.  The clinical development of MEK inhibitors. [http:\/\/dx.doi.org\/10.1038\/nrclinonc.2014.83]. [PMID: 24840079].","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=30","first-page":"320","volume":"2","author":"Abe H.","year":"2011","unstructured":"Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, Sakamoto J, Matsumoto N, Miura T, Matsumura K, Seki N, Inaba T, Kawasaki H, Yamaguchi T, Kakefuda R, Nanayama T, Kurachi H, Hori Y, Yoshida T, Kakegawa J, Watanabe Y, Gilmartin AG, Richter MC, Moss KG, Laquerre SG.  Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate). [http:\/\/dx.doi.org\/10.1021\/ml200004g]. [PMID: 24900312].","journal-title":"ACS Med Chem Lett"},{"key":"ref=31","first-page":"15910","volume":"112","author":"Ludlow R.F.","year":"2015","unstructured":"Ludlow RF, Verdonk ML, Saini HK, Tickle IJ, Jhoti H.  Detection of secondary binding sites in proteins using fragment screening. [http:\/\/dx.doi.org\/10.1073\/pnas.1518946112]. [PMID: 26655740].","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=32","first-page":"6056","volume":"108","author":"Sadowsky J.D.","year":"2011","unstructured":"Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA.  Turning a protein kinase on or off from a single allosteric site  disulfide trapping. [http:\/\/dx.doi.org\/10.1073\/pnas.1102376108]. [PMID: 21430264].","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=33","first-page":"13933","volume":"54","author":"Kroon E.","year":"2015","unstructured":"Kroon E, Schulze JO, S\u00fc\u00df E, Camacho CJ, Biondi RM, D\u00f6mling A.  Discovery of a potent allosteric kinase modulator by combining computational and synthetic methods. [http:\/\/dx.doi.org\/10.1002\/anie.201506310]. [PMID: 26385475].","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=34","first-page":"6743","volume":"19","author":"Shomin C.D.","year":"2011","unstructured":"Shomin CD, Restituyo E, Cox KJ, Ghosh I.  Selection of cyclic-peptide inhibitors targeting aurora kinase A: Problems and solutions. [http:\/\/dx.doi.org\/10.1016\/j.bmc.2011.09.049]. [PMID: 22004849].","journal-title":"Bioorg Med Chem"},{"key":"ref=35","first-page":"842","volume":"4","author":"Carmena M.","year":"2003","unstructured":"Carmena M, Earnshaw WC.  The cellular geography of aurora kinases. [http:\/\/dx.doi.org\/10.1038\/nrm1245]. [PMID: 14625535].","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=36","first-page":"537","volume":"34","author":"Goldenson B.","year":"2015","unstructured":"Goldenson B, Crispino JD.  The aurora kinases in cell cycle and leukemia. [http:\/\/dx.doi.org\/10.1038\/onc.2014.14]. [PMID: 24632603].","journal-title":"Oncogene"},{"key":"ref=37","first-page":"2987","volume":"120","author":"Barr A.R.","year":"2007","unstructured":"Barr AR, Gergely F.  Aurora-A: The maker and breaker of spindle poles. [http:\/\/dx.doi.org\/10.1242\/jcs.013136]. [PMID: 17715155].","journal-title":"J Cell Sci"},{"key":"ref=38","first-page":"640","volume":"12","author":"Berdnik D.","year":"2002","unstructured":"Berdnik D, Knoblich JA.  Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. [http:\/\/dx.doi.org\/10.1016\/S0960-9822(02)00766-2]. [PMID: 11967150].","journal-title":"Curr Biol"},{"key":"ref=39","first-page":"1109","volume":"155","author":"Hannak E.","year":"2001","unstructured":"Hannak E, Kirkham M, Hyman AA, Oegema K.  Aurora-A kinase is required for centrosome maturation in \n [http:\/\/dx.doi.org\/10.1083\/jcb.200108051]. [PMID: 11748251].","journal-title":"J Cell Biol"},{"key":"ref=40","first-page":"437","volume":"156","author":"Giet R.","year":"2002","unstructured":"Giet R, McLean D, Descamps S, Lee MJ, Raff JW, Prigent C, Glover DM.  Drosophila aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. [http:\/\/dx.doi.org\/10.1083\/jcb.200108135]. [PMID: 11827981].","journal-title":"J Cell Biol"},{"key":"ref=41","first-page":"1059","volume":"29","author":"Cowley D.O.","year":"2009","unstructured":"Cowley DO, Rivera-P\u00e9rez JA, Schliekelman M, He YJ, Oliver TG, Lu L, O\u2019Quinn R, Salmon ED, Magnuson T, Van Dyke T.  Aurora-A kinase is essential for bipolar spindle formation and early development. [http:\/\/dx.doi.org\/10.1128\/MCB.01062-08]. [PMID: 19075002].","journal-title":"Mol Cell Biol"},{"key":"ref=42","first-page":"289","volume":"182","author":"Bird A.W.","year":"2008","unstructured":"Bird AW, Hyman AA.  Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. [http:\/\/dx.doi.org\/10.1083\/jcb.200802005]. [PMID: 18663142].","journal-title":"J Cell Biol"},{"key":"ref=43","first-page":"1639","volume":"14","author":"Gautschi O.","year":"2008","unstructured":"Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR.  Aurora kinases as anticancer drug targets. [http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-07-2179]. [PMID: 18347165].","journal-title":"Clin Cancer Res"},{"key":"ref=44","first-page":"52175","volume":"279","author":"Liu Q.","year":"2004","unstructured":"Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, Cheng JQ.  Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. [http:\/\/dx.doi.org\/10.1074\/jbc.M406802200]. [PMID: 15469940].","journal-title":"J Biol Chem"},{"key":"ref=45","first-page":"51","volume":"3","author":"Anand S.","year":"2003","unstructured":"Anand S, Penrhyn-Lowe S, Venkitaraman AR.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. [http:\/\/dx.doi.org\/10.1016\/S1535-6108(02)00235-0]. [PMID: 12559175].","journal-title":"Cancer Cell"},{"key":"ref=46","first-page":"11","volume":"12","author":"Willems E.","year":"2017","unstructured":"Willems E, Lombard A, Dedobbeleer M, Goffart N, Rogister B.  The unexpected roles of Aurora A kinase in gliobastoma recurrences. [http:\/\/dx.doi.org\/10.1007\/s11523-016-0457-2].","journal-title":"Target Oncol"},{"key":"ref=47","first-page":"780","volume":"14","author":"Boss D.S.","year":"2009","unstructured":"Boss DS, Beijnen JH, Schellens JH.  Clinical experience with aurora kinase inhibitors: A review. [http:\/\/dx.doi.org\/10.1634\/theoncologist.2009-0019]. [PMID: 19684075].","journal-title":"Oncologist"},{"key":"ref=48","volume":"6","author":"Burgess S.G.","year":"2016","unstructured":"Burgess SG, Oleksy A, Cavazza T, Richards MW, Vernos I, Matthews D, Bayliss R.  Allosteric inhibition of Aurora-A kinase by a synthetic vNAR domain. [http:\/\/dx.doi.org\/10.1098\/rsob.160089]. [PMID: 27411893].","journal-title":"Open Biol"},{"key":"ref=49","first-page":"851","volume":"12","author":"Bayliss R.","year":"2003","unstructured":"Bayliss R, Sardon T, Vernos I, Conti E.  Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. [http:\/\/dx.doi.org\/10.1016\/S1097-2765(03)00392-7]. [PMID: 14580337].","journal-title":"Mol Cell"},{"key":"ref=50","first-page":"3383","volume":"11","author":"Rennie Y.K.","year":"2016","unstructured":"Rennie YK, McIntyre PJ, Akindele T, Bayliss R, Jamieson AGA.  TPX2 proteomimetic has enhanced affinity for Aurora-A due to hydrocarbon stapling of a helix. [http:\/\/dx.doi.org\/10.1021\/acschembio.6b00727]. [PMID: 27775325].","journal-title":"ACS Chem Biol"},{"key":"ref=51","first-page":"617","volume":"158","author":"Kufer T.A.","year":"2002","unstructured":"Kufer TA, Sillj\u00e9 HH, K\u00f6rner R, Gruss OJ, Meraldi P, Nigg EA.  Human TPX2 is required for targeting Aurora-A kinase to the spindle. [http:\/\/dx.doi.org\/10.1083\/jcb.200204155]. [PMID: 12177045].","journal-title":"J Cell Biol"},{"key":"ref=52","first-page":"10287","volume":"46","author":"Anderson K.","year":"2007","unstructured":"Anderson K, Yang J, Koretke K, Nurse K, Calamari A, Kirkpatrick RB, Patrick D, Silva D, Tummino PJ, Copeland RA, Lai Z.  Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. [http:\/\/dx.doi.org\/10.1021\/bi7011355]. [PMID: 17705509].","journal-title":"Biochemistry"},{"key":"ref=53","unstructured":""},{"key":"ref=54","first-page":"1949","volume":"16","author":"Garuti L.","year":"2009","unstructured":"Garuti L, Roberti M, Bottegoni G.  Small molecule aurora kinases inhibitors. [http:\/\/dx.doi.org\/10.2174\/092986709788682227]. [PMID: 19519375].","journal-title":"Curr Med Chem"},{"key":"ref=55","unstructured":""},{"key":"ref=56","first-page":"28528","volume":"6","author":"Jane\u010dek M.","year":"2016","unstructured":"Jane\u010dek M, Rossmann M, Sharma P, Emery A, Huggins DJ, Stockwell SR, Stokes JE, Tan YS, Almeida EG, Hardwick B, Narvaez AJ, Hyv\u00f6nen M, Spring DR, McKenzie GJ, Venkitaraman AR.  Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. [http:\/\/dx.doi.org\/10.1038\/srep28528]. [PMID: 27339427].","journal-title":"Sci Rep"},{"key":"ref=57","first-page":"208","volume":"6","author":"Huggins D.J.","year":"2011","unstructured":"Huggins DJ, Venkitaraman AR, Spring DR.  Rational methods for the selection of diverse screening compounds. [http:\/\/dx.doi.org\/10.1021\/cb100420r]. [PMID: 21261294].","journal-title":"ACS Chem Biol"},{"key":"ref=58","first-page":"9038","volume":"65","author":"Emanuel S.","year":"2005","unstructured":"Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes-Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA.  The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. [http:\/\/dx.doi.org\/10.1158\/0008-5472.CAN-05-0882]. [PMID: 16204078].","journal-title":"Cancer Res"},{"key":"ref=59","first-page":"585","volume":"114","author":"Hirota T.","year":"2003","unstructured":"Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M, Hatakeyama K, Saya H.  Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. [http:\/\/dx.doi.org\/10.1016\/S0092-8674(03)00642-1]. [PMID: 13678582].","journal-title":"Cell"},{"key":"ref=60","first-page":"147","volume":"11","author":"Hutterer A.","year":"2006","unstructured":"Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA.  Mitotic activation of the kinase Aurora-A requires its binding partner Bora. [http:\/\/dx.doi.org\/10.1016\/j.devcel.2006.06.002]. [PMID: 16890155].","journal-title":"Dev Cell"},{"key":"ref=61","first-page":"744","volume":"22","author":"Dauch D.","year":"2016","unstructured":"Dauch D, Rudalska R, Cossa G, Nault JC, Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L, Pantsar T, Bozko P, Malek NP, Longerich T, Laufer S, Poso A, Zucman-Rossi J, Eilers M, Zender L.  A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. [http:\/\/dx.doi.org\/10.1038\/nm.4107]. [PMID: 27213815].","journal-title":"Nat Med"},{"key":"ref=62","first-page":"13726","volume":"113","author":"Richards M.W.","year":"2016","unstructured":"Richards MW, Burgess SG, Poon E, Carstensen A, Eilers M, Chesler L, Bayliss R.  Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. [http:\/\/dx.doi.org\/10.1073\/pnas.1610626113]. [PMID: 27837025].","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=63","first-page":"792","volume":"51","author":"Kishore A.H.","year":"2008","unstructured":"Kishore AH, Vedamurthy BM, Mantelingu K, Agrawal S, Reddy BA, Roy S, Rangappa KS, Kundu TK.  Specific small-molecule activator of Aurora kinase A induces autophosphorylation in a cell-free system. [http:\/\/dx.doi.org\/10.1021\/jm700954w]. [PMID: 18215015].","journal-title":"J Med Chem"},{"key":"ref=64","first-page":"175","volume":"44","author":"Sullivan J.T.","year":"1982","unstructured":"Sullivan JT, Richards CS, Lloyd HA, Krishna G.  Anacardic acid: molluscicide in cashew nut shell liquid. [http:\/\/dx.doi.org\/10.1055\/s-2007-971434]. [PMID: 17402106].","journal-title":"Planta Med"},{"key":"ref=65","first-page":"10416","volume":"111","author":"Karthigeyan D.","year":"2014","unstructured":"Karthigeyan D, Siddhanta S, Kishore AH, Perumal SSRR, \u00c5gren H, Sudevan S, Bhat AV, Balasubramanyam K, Subbegowda RK, Kundu TK, Narayana C.  SERS and MD simulation studies of a kinase inhibitor demonstrate the emergence of a potential drug discovery tool. [http:\/\/dx.doi.org\/10.1073\/pnas.1402695111]. [PMID: 24972791].","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=66","first-page":"20057","volume":"119","author":"Kumari G.","year":"2015","unstructured":"Kumari G, Kandula J, Narayana C.  How far can we probe by SERS? [http:\/\/dx.doi.org\/10.1021\/acs.jpcc.5b07556].","journal-title":"J Phys Chem C"},{"key":"ref=67","first-page":"113","volume":"4","author":"P\u00e9rez-Pineiro R.","year":"2012","unstructured":"P\u00e9rez-Pineiro R, Correa-Duarte MA, Salgueirino V, Alvarez-Puebla RA.  SERS assisted ultra-fast peptidic screening: A new tool for drug discovery. [http:\/\/dx.doi.org\/10.1039\/C1NR11293G]. [PMID: 22071599].","journal-title":"Nanoscale"},{"key":"ref=68","first-page":"5567","volume":"9","author":"Costas C.","year":"2015","unstructured":"Costas C, L\u00f3pez-Puente V, Bodel\u00f3n G, Gonz\u00e1lez-Bello C, P\u00e9rez-Juste J, Pastoriza-Santos I, Liz-Marz\u00e1n LM.  Using surface enhanced Raman scattering to analyze the interactions of protein receptors with bacterial quorum sensing modulators. [http:\/\/dx.doi.org\/10.1021\/acsnano.5b01800]. [PMID: 25927541].","journal-title":"ACS Nano"},{"key":"ref=69","first-page":"9016","volume":"52","author":"Siddhanta S.","year":"2016","unstructured":"Siddhanta S, Wr\u00f3bel MS, Barman I.  Integration of protein tethering in a rapid and label-free SERS screening platform for drugs of abuse. [http:\/\/dx.doi.org\/10.1039\/ C6CC00518G]. [PMID: 27002230].","journal-title":"Chem Commun (Camb)"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/154518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:06:48Z","timestamp":1573643208000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/154518\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":69,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,7,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867324666170727120315","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}